A Breast Lump with Discordant Receptor Status
A 52-year-old woman presents with a 2.5 cm firm, irregular mass in the right breast. Core biopsy shows invasive ductal carcinoma, grade 3, with lymphovascular invasion. Immunohistochemistry reports oestrogen receptor (ER) positive in 80% of cells, progesterone receptor (PR) negative, HER2 score 2+ by immunohistochemistry, and Ki-67 45%. Fluorescence in situ hybridisation for HER2 is not amplified. A sentinel lymph node biopsy shows micrometastasis (0.8 mm). Staging scans show no distant disease. The multidisciplinary team debates whether she should receive neoadjuvant chemotherapy, endocrine therapy, or both, and whether HER2-directed therapy has a role.
1. Interpret the receptor and proliferation data in the context of tumour biology, and explain the rationale for the treatment options being considered.
Read the worked answer
The tumour is ER-positive but PR-negative, with high Ki-67 and grade 3 morphology. This profile suggests a luminal B-like subtype, which is characterised by higher proliferation and more aggressive behaviour than luminal A. ER positivity indicates that the tumour is driven by oestrogen signalling, so endocrine therapy is a cornerstone. However, the absence of PR and high Ki-67 suggest relative endocrine resistance and a greater benefit from chemotherapy. HER2 is not amplified (FISH negative, IHC 2+), so HER2-directed therapy is not indicated. The presence of lymphovascular invasion and a micrometastasis in the sentinel node increases the risk of recurrence, supporting consideration of adjuvant chemotherapy. Neoadjuvant chemotherapy could be used to downstage the primary tumour and test chemosensitivity, but the tumour is hormone receptor-positive and may not shrink as dramatically as HER2-positive or triple-negative cancers. The judgement is to weigh the aggressive features (grade 3, high Ki-67, nodal micrometastasis) against the ER positivity, and to recognise that this is a luminal B cancer where chemotherapy plus endocrine therapy is likely to offer the best risk reduction, while HER2 therapy is not justified.
2. How would you explain the significance of the sentinel node micrometastasis and the choice of adjuvant therapy to the patient?
Read the worked answer
The sentinel node micrometastasis (0.8 mm) is a small deposit of cancer cells in the first draining lymph node. It indicates that tumour cells have begun to spread via lymphatics, which increases the risk of recurrence compared with node-negative disease, but it is not the same as macroscopic nodal involvement. In many guidelines, micrometastasis is considered node-positive for staging and may influence the decision to give adjuvant chemotherapy, especially when other risk factors such as high grade, lymphovascular invasion, and high Ki-67 are present. The patient should understand that her cancer is hormone-sensitive, so endocrine therapy (e.g., tamoxifen or an aromatase inhibitor depending on menopausal status) will reduce the risk of recurrence by blocking oestrogen signalling. Chemotherapy is being considered because the tumour has aggressive features that predict a higher chance of micrometastatic disease elsewhere. The absence of HER2 amplification means trastuzumab is not appropriate. The discussion should include the absolute benefit of chemotherapy, which may be modest but meaningful given her risk profile, and the potential side effects. The judgement is to communicate uncertainty and involve the patient in a shared decision, recognising that the micrometastasis is a risk marker rather than a guarantee of systemic spread.